The MEA human papillomavirus (HPV) vaccine market is expected to grow from US$ 82.91 million in 2022 to US$ 100.86 million by 2028; it is estimated to grow at a CAGR of 3.3% from 2022 to 2028.
Healthcare organizations have developed and adopted several strategies to prevent and eliminate HPV infections. The World Health Assembly, in August 2020, adopted the strategy for cervical cancer elimination. As per the strategy, to eliminate cervical cancer, all countries across the region must reach and maintain an incidence rate of below four per 100,000 women. To reduce the incidence rate of cervical cancer, countries should focus on vaccination, screening, and treatment of cervical cancer. In 2016, Gavi Board initiated an HPV vaccine program. That allows countries in their first year of the program to scale up and vaccinate girls between the age of 9 and 14 years. Through this new strategy, Gavi aimed to protect about 40 million girls from cervical cancer by 2020, preventing an estimated 900,000 deaths. Many countries accepted the Gavi support and introduced the HPV vaccine in their national immunization program. Countries with the highest burden of cervical cancer, initiated the Gavi HPV vaccine program. All these initiatives are aiding the HPV vaccines market substantially across the region.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the MEA human papillomavirus (HPV) vaccine market . The MEA human papillomavirus (HPV) vaccine market is expected to grow at a good CAGR during the forecast period.
Healthcare organizations have developed and adopted several strategies to prevent and eliminate HPV infections. The World Health Assembly, in August 2020, adopted the strategy for cervical cancer elimination. As per the strategy, to eliminate cervical cancer, all countries across the region must reach and maintain an incidence rate of below four per 100,000 women. To reduce the incidence rate of cervical cancer, countries should focus on vaccination, screening, and treatment of cervical cancer. In 2016, Gavi Board initiated an HPV vaccine program. That allows countries in their first year of the program to scale up and vaccinate girls between the age of 9 and 14 years. Through this new strategy, Gavi aimed to protect about 40 million girls from cervical cancer by 2020, preventing an estimated 900,000 deaths. Many countries accepted the Gavi support and introduced the HPV vaccine in their national immunization program. Countries with the highest burden of cervical cancer, initiated the Gavi HPV vaccine program. All these initiatives are aiding the HPV vaccines market substantially across the region.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the MEA human papillomavirus (HPV) vaccine market . The MEA human papillomavirus (HPV) vaccine market is expected to grow at a good CAGR during the forecast period.
MEA Human Papillomavirus (HPV) Vaccine Market Segmentation
The MEA human papillomavirus (HPV) vaccine market is segmented based on type, dosage, age, application, end user, and country.- Based on type, the MEA human papillomavirus (HPV) vaccine market is segmented into 9-valent HPV vaccine, quadrivalent HPV vaccine, and bivalent HPV vaccine. The quadrivalent HPV vaccine segment dominated the market in 2022.
- Based on dosage, the MEA human papillomavirus (HPV) vaccine market is bifurcated into 2 dose and 3 dose. The 2 dose segment dominated the market in 2022.
- Based on age, the MEA human papillomavirus (HPV) vaccine market is bifurcated into 9 to 14 years and 15 to 45 years. The 9 to 14 years segment dominated the market in 2022.
- Based on application, the MEA human papillomavirus (HPV) vaccine market is bifurcated into HPV-attributable cancer and genital warts. The HPV-attributable cancer segment dominated the market in 2022.
- Based on end user, the MEA human papillomavirus (HPV) vaccine market is segmented into doctors office, community health clinics, school-based health centers, health departments, hospitals, and others. The hospitals segment dominated the market in 2022.
- Based on country, the MEA human papillomavirus (HPV) vaccine market has been categorized into Saudi Arabia, South Africa, the UAE, Iran, Turkey, Kuwait, Bahrain, Egypt, and the Rest of MEA. Saudi Arabia would dominate the market in 2022.
Table of Contents
1. Introduction
3. Research Methodology
4. MEA Human Papillomavirus (HPV) Vaccine Market - Market Landscape
5. MEA Human Papillomavirus (HPV) Vaccine Market - Key Market Dynamics
6. Human Papillomavirus (HPV) Vaccine Market- MEA Analysis
7. MEA Human Papillomavirus (HPV) Vaccine Market Analysis - By Type
8. MEA Human Papillomavirus (HPV) Vaccine Market Analysis - By Dosage
9. MEA Human Papillomavirus (HPV) Vaccine Market Analysis - By Age
10. MEA Human Papillomavirus (HPV) Vaccine Market Analysis - By Application
11. MEA Human Papillomavirus (HPV) Vaccine Market Analysis - By End User
12. MEA Human Papillomavirus (HPV) Vaccine Market - Country Analysis
13. Industry Landscape
14. Company Profiles
15. Appendix
Companies Mentioned
- GlaxoSmithKline plc.
- Inovio Pharmaceuticals
- Merck & Co., Inc.
- R-Pharm
- Sanofi
- Serum Institute of India Pvt. Ltd
- Walvax Biotechnology Co., Ltd.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 150 |
Published | September 2022 |
Forecast Period | 2022 - 2028 |
Estimated Market Value ( USD | $ 82.91 Million |
Forecasted Market Value ( USD | $ 100.86 Million |
Compound Annual Growth Rate | 3.3% |
Regions Covered | Africa, Middle East |
No. of Companies Mentioned | 7 |